Aoki, Tadashi
Ito, Hideki
Ogura, Takehisa
Hirata, Ayako
Nishiwaki, Yuji
Kameda, Hideto
Funding for this research was provided by:
JSPS KAKENHI (JP15K09535)
The Ministry of Health, Labor and Welfare of Japan (Health and Labor Sciences Research Grants for research on intractable diseases (The Research Team for Autoimmune Diseases))
Article History
Received: 12 March 2020
Accepted: 27 August 2020
First Online: 17 September 2020
Competing interests
: This work was partly supported by JSPS KAKENHI Grant Number JP15K09535, Health and Labor Sciences Research Grants for research on intractable diseases (The Research Team for Autoimmune Diseases) from the Ministry of Health, Labor and Welfare of Japan for H. K. H. K. has received consulting fees, speaking fees, and/or honoraria from AbbVie G.K., Asahi Kasei Pharma, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Gilead Sciences, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Novartis Pharma K.K., and Sanofi Pharma, and has received research grants from AbbVie G.K., Asahi Kasei Pharma, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma, Novartis Pharma K.K. and Sanofi Pharma. T. A., H. I., T. O., A. H. and Y. N. declare no potential conflict of interest.